Erste Asset Management Gmb H Sarepta Therapeutics, Inc. Transaction History

Erste Asset Management Gmb H

$11.9 Trillion
Q2 2025

A detailed history of Erste Asset Management Gmb H transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Erste Asset Management Gmb H holds 1,621,415 shares of SRPT stock, worth $27.6 Million. This represents 0.23% of its overall portfolio holdings.

Number of Shares

1,621,415

Previous 1,061,065 52.81%

Holding current value

$27.6 Million

Previous $62.8 Billion 55.82%

% of portfolio

0.23%

Previous 0.81%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$17.1 - $63.66 $9.58 Million - $35.7 Million	560,350 Added 52.81%	1,621,415 $27.7 Billion
Q1 2025 May 14, 2025	BUY	$63.82 - $127.89 $22.5 Million - $45.1 Million	352,817 Added 49.82%	1,061,065 $62.8 Billion
Q4 2024 Feb 10, 2025	BUY	$104.54 - $137.94 $7.55 Million - $9.96 Million	72,183 Added 11.35%	708,248 $76 Billion
Q3 2024 Nov 14, 2024	BUY	$124.33 - $156.75 $79.1 Million - $99.7 Million	636,065 New	636,065 $79.4 Billion
Q2 2024 Nov 26, 2024	SELL	$113.33 - $163.85 $5.67 Million - $8.19 Million	-50,000 Reduced 8.75%	521,400 $82.4 Billion
Q1 2024 Nov 26, 2024	SELL	$93.7 - $141.53 $12.2 Million - $18.4 Million	-130,000 Reduced 18.53%	571,400 $74 Billion
Q4 2023 Nov 26, 2024	BUY	$67.31 - $124.76 $1.08 Million - $2 Million	16,000 Added 2.33%	701,400 $67.7 Billion
Q3 2023 Nov 26, 2024	BUY	$102.5 - $123.59 $7.28 Million - $8.77 Million	71,000 Added 11.56%	685,400 $83.2 Billion
Q2 2023 Nov 26, 2024	BUY	$106.4 - $157.19 $7.66 Million - $11.3 Million	72,000 Added 11.1%	720,860 $82.3 Billion
Q1 2023 Nov 26, 2024	SELL	$117.53 - $155.99 $2.7 Million - $3.59 Million	-23,000 Reduced 3.42%	648,860 $89.3 Billion
Q4 2022 Nov 26, 2024	SELL	$100.86 - $132.13 $16.6 Million - $21.7 Million	-164,460 Reduced 21.12%	614,400 $79.5 Billion
Q3 2022 Nov 26, 2024	BUY	$75.71 - $119.24 $2.71 Million - $4.27 Million	35,795 Added 5.63%	671,860 $74.2 Billion
Q2 2022 Nov 26, 2024	BUY	$62.69 - $88.44 $16.9 Million - $23.9 Million	270,050 Added 53.07%	778,860 $58.6 Billion
Q1 2022 Nov 22, 2024	SELL	$63.15 - $90.42 $4.69 Million - $6.71 Million	-74,200 Reduced 8.7%	778,860 $60.9 Billion
Q4 2021 Nov 22, 2024	BUY	$77.28 - $99.42 $17.4 Million - $22.3 Million	224,795 Added 35.34%	860,860 $78 Billion
Q3 2021 Nov 22, 2024	BUY	$65.97 - $92.48 $1.98 Million - $2.77 Million	30,000 Added 3.64%	853,060 $78.8 Billion
Q2 2021 Nov 22, 2024	BUY	$69.38 - $86.75 $12.6 Million - $15.7 Million	181,500 Added 28.29%	823,060 $64 Billion
Q1 2021 Nov 22, 2024	BUY	$72.25 - $168.95 $18.9 Million - $44.1 Million	261,250 Added 68.69%	641,560 $47.8 Billion
Q4 2020 Nov 22, 2024	BUY	$125.56 - $178.74 $998,202 - $1.42 Million	7,950 Added 2.14%	380,310 $65.3 Billion
Q3 2020 Nov 22, 2024	SELL	$127.12 - $172.34 $33.5 Million - $45.4 Million	-263,705 Reduced 41.46%	372,360 $52.4 Billion
Q2 2020 Nov 22, 2024	SELL	$93.0 - $171.7 $2.33 Million - $4.29 Million	-25,000 Reduced 5.86%	401,260 $64.6 Billion
Q1 2020 Nov 22, 2024	SELL	$82.38 - $131.64 $11.9 Million - $19 Million	-144,000 Reduced 25.25%	426,260 $41.8 Billion
Q4 2019 Nov 22, 2024	SELL	$76.53 - $135.58 $5.04 Million - $8.92 Million	-65,805 Reduced 10.35%	570,260 $73.6 Billion
Q3 2019 Nov 22, 2024	BUY	$72.81 - $156.91 $1.12 Million - $2.42 Million	15,440 Added 2.9%	548,660 $41.3 Billion
Q2 2019 Nov 22, 2024	BUY	$112.21 - $151.95 $1.13 Million - $1.53 Million	10,100 Added 1.93%	533,220 $78.6 Billion
Q1 2019 Nov 22, 2024	SELL	$106.67 - $151.68 $12 Million - $17.1 Million	-112,945 Reduced 17.76%	523,120 $62.3 Billion
Q4 2018 Nov 26, 2024	SELL	$97.32 - $148.76 $12.4 Million - $18.9 Million	-127,255 Reduced 20.01%	508,810 $54.8 Billion

Others Institutions Holding SRPT

# of Institutions

463

Shares Held

83.3M

Call Options Held

5.6M

Put Options Held

4.19M

View Full List

About Sarepta Therapeutics, Inc.

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $1.49B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

More about SRPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Erste Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Erste Asset Management Gmb H with notifications on news.

Account

Erste Asset Management Gmb H Sarepta Therapeutics, Inc. Transaction History